Cancer BiologybioRxivPreprint
Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
A. P. Bidkar, S. Wang, K. N. Bobba…·R. R. Flavell
This study develops and evaluates [225Ac]DOTA-YS5, a radioimmunotherapy for prostate cancer, showing high efficacy in xenograft models but nephrotoxicity at higher doses.
DOI 10.1101/2022.10.13.512165